These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9246152)

  • 1. Phase II trial of topotecan in malignant melanoma.
    Kraut EH; Walker MJ; Staubus A; Gochnour D; Balcerzak SP
    Cancer Invest; 1997; 15(4):318-20. PubMed ID: 9246152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.
    Verweij J; Lund B; Beijnen J; Planting A; de Boer-Dennert M; Koier I; Rosing H; Hansen H
    Ann Oncol; 1993 Sep; 4(8):673-8. PubMed ID: 8240998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
    Saltz L; Janik JE
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-26-S5-30. PubMed ID: 9122740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of topotecan in metastatic hormone-refractory prostate cancer.
    Hudes GR; Kosierowski R; Greenberg R; Ramsey HE; Fox SC; Ozols RF; McAleer CA; Giantonio BJ
    Invest New Drugs; 1995; 13(3):235-40. PubMed ID: 8729952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma.
    Bramwell VH; Eisenhauer EA; Blackstein M; Boos G; Knowling M; Jolivet J; Bogues W
    Ann Oncol; 1995 Oct; 6(8):847-9. PubMed ID: 8589028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
    Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
    Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of topotecan for pediatric central nervous system tumors.
    Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
    Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
    Wall JG; Burris HA; Von Hoff DD; Rodriguez G; Kneuper-Hall R; Shaffer D; O'Rourke T; Brown T; Weiss G; Clark G
    Anticancer Drugs; 1992 Aug; 3(4):337-45. PubMed ID: 1330081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
    Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
    J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group.
    Macdonald D; Cairncross G; Stewart D; Forsyth P; Sawka C; Wainman N; Eisenhauer E
    Ann Oncol; 1996 Feb; 7(2):205-7. PubMed ID: 8777179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas.
    Scher RM; Kosierowski R; Lusch C; Alexander R; Fox S; Redei I; Green F; Raskay B; Amfoh K; Engstrom PF; O'Dwyer PJ
    Invest New Drugs; 1996; 13(4):347-54. PubMed ID: 8824355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
    J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
    Burris HA; Awada A; Kuhn JG; Eckardt JR; Cobb PW; Rinaldi DA; Fields S; Smith L; Von Hoff DD
    Anticancer Drugs; 1994 Aug; 5(4):394-402. PubMed ID: 7949242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; Ellis A; Zwelling L; O'Brien S; Cazenave L; Koller C; Rios MB; Plunkett W; Keating MJ
    Blood; 1993 Mar; 81(5):1146-51. PubMed ID: 8382970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
    Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
    Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of topotecan for pediatric patients with malignant solid tumors.
    Pratt CB; Stewart C; Santana VM; Bowman L; Furman W; Ochs J; Marina N; Kuttesch JF; Heideman R; Sandlund JT
    J Clin Oncol; 1994 Mar; 12(3):539-43. PubMed ID: 8120551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
    Tubergen DG; Stewart CF; Pratt CB; Zamboni WC; Winick N; Santana VM; Dryer ZA; Kurtzberg J; Bell B; Grier H; Vietti TJ
    J Pediatr Hematol Oncol; 1996 Nov; 18(4):352-61. PubMed ID: 8888741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of topotecan in patients with previously untreated pancreatic cancer.
    O'Reilly S; Donehower RC; Rowinsky EK; Ord S; Grochow LB
    Anticancer Drugs; 1996 Jun; 7(4):410-4. PubMed ID: 8826609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
    Creemers GJ; Bolis G; Gore M; Scarfone G; Lacave AJ; Guastalla JP; Despax R; Favalli G; Kreinberg R; Van Belle S; Hudson I; Verweij J; Ten Bokkel Huinink WW
    J Clin Oncol; 1996 Dec; 14(12):3056-61. PubMed ID: 8955650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.